BofA Securities Reiterates Underperform Rating on Moderna (MRNA) After Virtual Analyst Day Focuses Only on C19 and an Immature Pipeline
Tweet Send to a Friend
BofA Securities analyst Geoff Meacham reiterated an Underperform rating and $135.00 price target on Moderna (NASDAQ: MRNA) after attending the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
